(CDXS) Codexis - Overview
Exchange: NASDAQ •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US1920051067
Stock: Enzymes, Therapeutics, RNAi, Platform, Manufacturing
Total Rating 7
Risk 36
Buy Signal -1.60
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 89.1% |
| Relative Tail Risk | -10.2% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -1.16 |
| Alpha | -95.64 |
| Character TTM | |
|---|---|
| Beta | 1.904 |
| Beta Downside | 1.287 |
| Drawdowns 3y | |
|---|---|
| Max DD | 78.88% |
| CAGR/Max DD | -0.50 |
Description: CDXS Codexis January 02, 2026
Codexis, Inc. (NASDAQ: CDXS) commercializes proprietary enzymatic technologies for the manufacturing of therapeutic biologics, most notably through its CodeEvolver platform that engineers novel enzymes for use across global markets. Its ECO Synthesis system targets the large-scale production of RNA-interference (RNAi) drugs via an enzymatic route, and the firm holds strategic licensing agreements with Aldevron and Pfizer to accelerate commercialization.
Key recent metrics: the company reported FY 2023 revenue of $85 million, a 22 % YoY increase driven by expanding enzyme-as-a-service contracts; cash and equivalents stood at $150 million, providing roughly 18 months of runway at current burn rates; and the global enzyme market is projected to grow at a 6.5 % CAGR through 2030, underpinning demand for Codexis’s high-purity biocatalysts. Sector drivers include rising adoption of biologics, cost-pressure on traditional chemical synthesis, and regulatory incentives for greener manufacturing processes.
For a deeper quantitative assessment, the ValueRay platform offers a granular breakdown of CDXS’s valuation metrics and scenario analyses.
Piotroski VR‑10 (Strict, 0-10) 1.5
| Net Income: -64.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.50 > 0.02 and ΔFCF/TA -18.61 > 1.0 |
| NWC/Revenue: 109.0% < 20% (prev 120.7%; Δ -11.64% < -1%) |
| CFO/TA -0.45 > 3% & CFO -55.9m > Net Income -64.0m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 4.12 > 1.5 & < 3 |
| Outstanding Shares: last quarter (90.3m) vs 12m ago 25.29% < -2% |
| Gross Margin: 79.31% > 18% (prev 0.72%; Δ 7859 % > 0.5%) |
| Asset Turnover: 38.90% > 50% (prev 43.49%; Δ -4.59% > 0%) |
| Interest Coverage Ratio: -19.55 > 6 (EBITDA TTM -55.3m / Interest Expense TTM -3.20m) |
Altman Z'' -15.00
| A: 0.47 (Total Current Assets 76.2m - Total Current Liabilities 18.5m) / Total Assets 124.0m |
| B: -4.97 (Retained Earnings -616.4m / Total Assets 124.0m) |
| C: -0.46 (EBIT TTM -62.6m / Avg Total Assets 136.1m) |
| D: -7.22 (Book Value of Equity -616.4m / Total Liabilities 85.4m) |
| Altman-Z'' Score: -23.83 = D |
Beneish M -3.67
| DSRI: 0.72 (Receivables 9.73m/16.5m, Revenue 52.9m/64.4m) |
| GMI: 0.91 (GM 79.31% / 72.13%) |
| AQI: 0.77 (AQ_t 0.06 / AQ_t-1 0.08) |
| SGI: 0.82 (Revenue 52.9m / 64.4m) |
| TATA: -0.06 (NI -64.0m - CFO -55.9m) / TA 124.0m) |
| Beneish M-Score: -3.67 (Cap -4..+1) = AAA |
What is the price of CDXS shares?
As of February 08, 2026, the stock is trading at USD 1.33 with a total of 1,202,241 shares traded.
Over the past week, the price has changed by +7.26%, over one month by -22.67%, over three months by -34.64% and over the past year by -69.70%.
Over the past week, the price has changed by +7.26%, over one month by -22.67%, over three months by -34.64% and over the past year by -69.70%.
Is CDXS a buy, sell or hold?
Codexis has received a consensus analysts rating of 4.29.
Therefore, it is recommended to buy CDXS.
- StrongBuy: 4
- Buy: 1
- Hold: 2
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the CDXS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 6.6 | 394.7% |
| Analysts Target Price | 6.6 | 394.7% |
| ValueRay Target Price | 0.9 | -34.6% |
CDXS Fundamental Data Overview February 03, 2026
P/E Forward = 138.8889
P/S = 2.116
P/B = 2.9293
P/EG = -1.16
Revenue TTM = 52.9m USD
EBIT TTM = -62.6m USD
EBITDA TTM = -55.3m USD
Long Term Debt = 39.7m USD (from longTermDebt, last quarter)
Short Term Debt = 3.09m USD (from shortTermDebt, last quarter)
Debt = 68.6m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 42.8m USD (from netDebt column, last quarter)
Enterprise Value = 121.4m USD (112.0m + Debt 68.6m - CCE 59.2m)
Interest Coverage Ratio = -19.55 (Ebit TTM -62.6m / Interest Expense TTM -3.20m)
EV/FCF = -1.97x (Enterprise Value 121.4m / FCF TTM -61.7m)
FCF Yield = -50.78% (FCF TTM -61.7m / Enterprise Value 121.4m)
FCF Margin = -116.5% (FCF TTM -61.7m / Revenue TTM 52.9m)
Net Margin = -120.8% (Net Income TTM -64.0m / Revenue TTM 52.9m)
Gross Margin = 79.31% ((Revenue TTM 52.9m - Cost of Revenue TTM 10.9m) / Revenue TTM)
Gross Margin QoQ = 71.34% (prev 86.31%)
Tobins Q-Ratio = 0.98 (Enterprise Value 121.4m / Total Assets 124.0m)
Interest Expense / Debt = 1.88% (Interest Expense 1.29m / Debt 68.6m)
Taxrate = 21.0% (US default 21%)
NOPAT = -49.5m (EBIT -62.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 4.12 (Total Current Assets 76.2m / Total Current Liabilities 18.5m)
Debt / Equity = 1.78 (Debt 68.6m / totalStockholderEquity, last quarter 38.5m)
Debt / EBITDA = -0.77 (negative EBITDA) (Net Debt 42.8m / EBITDA -55.3m)
Debt / FCF = -0.69 (negative FCF - burning cash) (Net Debt 42.8m / FCF TTM -61.7m)
Total Stockholder Equity = 52.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -47.00% (Net Income -64.0m / Total Assets 124.0m)
RoE = -121.4% (Net Income TTM -64.0m / Total Stockholder Equity 52.7m)
RoCE = -67.77% (EBIT -62.6m / Capital Employed (Equity 52.7m + L.T.Debt 39.7m))
RoIC = -56.88% (negative operating profit) (NOPAT -49.5m / Invested Capital 87.0m)
WACC = 8.58% (E(112.0m)/V(180.6m) * Re(12.93%) + D(68.6m)/V(180.6m) * Rd(1.88%) * (1-Tc(0.21)))
Discount Rate = 12.93% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 13.96%
Fair Price DCF = unknown (Cash Flow -61.7m)
EPS Correlation: -0.99 | EPS CAGR: 8.05% | SUE: 0.78 | # QB: 0
Revenue Correlation: -69.61 | Revenue CAGR: -24.36% | SUE: -3.00 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.11 | Chg30d=+0.000 | Revisions Net=+1 | Analysts=1
EPS next Year (2026-12-31): EPS=-0.49 | Chg30d=+0.130 | Revisions Net=+1 | Growth EPS=+17.9% | Growth Revenue=+5.2%
P/S = 2.116
P/B = 2.9293
P/EG = -1.16
Revenue TTM = 52.9m USD
EBIT TTM = -62.6m USD
EBITDA TTM = -55.3m USD
Long Term Debt = 39.7m USD (from longTermDebt, last quarter)
Short Term Debt = 3.09m USD (from shortTermDebt, last quarter)
Debt = 68.6m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 42.8m USD (from netDebt column, last quarter)
Enterprise Value = 121.4m USD (112.0m + Debt 68.6m - CCE 59.2m)
Interest Coverage Ratio = -19.55 (Ebit TTM -62.6m / Interest Expense TTM -3.20m)
EV/FCF = -1.97x (Enterprise Value 121.4m / FCF TTM -61.7m)
FCF Yield = -50.78% (FCF TTM -61.7m / Enterprise Value 121.4m)
FCF Margin = -116.5% (FCF TTM -61.7m / Revenue TTM 52.9m)
Net Margin = -120.8% (Net Income TTM -64.0m / Revenue TTM 52.9m)
Gross Margin = 79.31% ((Revenue TTM 52.9m - Cost of Revenue TTM 10.9m) / Revenue TTM)
Gross Margin QoQ = 71.34% (prev 86.31%)
Tobins Q-Ratio = 0.98 (Enterprise Value 121.4m / Total Assets 124.0m)
Interest Expense / Debt = 1.88% (Interest Expense 1.29m / Debt 68.6m)
Taxrate = 21.0% (US default 21%)
NOPAT = -49.5m (EBIT -62.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 4.12 (Total Current Assets 76.2m / Total Current Liabilities 18.5m)
Debt / Equity = 1.78 (Debt 68.6m / totalStockholderEquity, last quarter 38.5m)
Debt / EBITDA = -0.77 (negative EBITDA) (Net Debt 42.8m / EBITDA -55.3m)
Debt / FCF = -0.69 (negative FCF - burning cash) (Net Debt 42.8m / FCF TTM -61.7m)
Total Stockholder Equity = 52.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -47.00% (Net Income -64.0m / Total Assets 124.0m)
RoE = -121.4% (Net Income TTM -64.0m / Total Stockholder Equity 52.7m)
RoCE = -67.77% (EBIT -62.6m / Capital Employed (Equity 52.7m + L.T.Debt 39.7m))
RoIC = -56.88% (negative operating profit) (NOPAT -49.5m / Invested Capital 87.0m)
WACC = 8.58% (E(112.0m)/V(180.6m) * Re(12.93%) + D(68.6m)/V(180.6m) * Rd(1.88%) * (1-Tc(0.21)))
Discount Rate = 12.93% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 13.96%
Fair Price DCF = unknown (Cash Flow -61.7m)
EPS Correlation: -0.99 | EPS CAGR: 8.05% | SUE: 0.78 | # QB: 0
Revenue Correlation: -69.61 | Revenue CAGR: -24.36% | SUE: -3.00 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.11 | Chg30d=+0.000 | Revisions Net=+1 | Analysts=1
EPS next Year (2026-12-31): EPS=-0.49 | Chg30d=+0.130 | Revisions Net=+1 | Growth EPS=+17.9% | Growth Revenue=+5.2%